SGM
CINC

Seven Grand Managers’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Seven Grand Managers’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$656K – 25
2022
Q3 		$656K Buy
+20,000
New +$565K 2.15% 13

Other funds holding CINC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Seven Grand Managers's CINC Position: Q4 2022 in Review

Seven Grand Managers sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q4 2022, closing a stake of 20,000 shares — an estimated $656K sold.

Seven Grand Managers first reported a position in CINC in Q3 2022 and held it in 1 quarter. The position peaked at $656K in Q3 2022. 102 funds tracked by Wall St. Rank hold CINC as of Q4 2022.

  • Seven Grand Managers reported no remaining CinCor Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Seven Grand Managers sold 20,000 CinCor Pharma, Inc. Common Stock shares in Q4 2022, an estimated $656K.
  • Seven Grand Managers first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Seven Grand Managers's CinCor Pharma, Inc. Common Stock position peaked at $656K in Q3 2022.
  • 102 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q4 2022.

Based on Seven Grand Managers's 13F filing for Q4 2022, filed 14 Feb 2023.